Page last updated: 2024-11-10

yya-021

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

YYA-021: an HIV entry inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3107635
CHEMBL ID610204
MeSH IDM000598122

Synonyms (26)

Synonym
AKOS000341495
CHEMBL610204
n'-(4-methylphenyl)-n-(2,2,6,6-tetramethylpiperidin-4-yl)oxamide
S7487
ethanediamide, n-(4-methylphenyl)-n'-(2,2,6,6-tetramethyl-4-piperidinyl)-
n-(p-tolyl)-n'-(2,2,6,6-tetramethyl-4-piperidyl)oxamide
n1-(2,2,6,6-tetramethylpiperidin-4-yl)-n2-(p-tolyl)oxalamide
n1-(2,2,6,6-tetramethylpiperidin-4-yl)-n2-p-tolyloxalamide
AM85586
144217-65-2
yya-021
AC-35366
SR-01000358779-1
sr-01000358779
CS-5582
HY-100039
EX-A1009
yya021
yya 021
mfcd00738763
NCGC00386395-01
BCP18096
A14296
MS-24688
n1-(4-methylphenyl)-n2-(2,2,6,6-tetramethyl-4-piperidinyl)-ethanediamide
A902772

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1058148Half life in Jcl:Sprague-Dawley rat at 2.5 mg/kg, iv by HPLC analysis2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
A CD4 mimic as an HIV entry inhibitor: pharmacokinetics.
AID516484Cytotoxicity against human PM1 cells expressing CCR5 by MTT assay2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.
AID763079Antiviral activity against Human immunodeficiency virus 1 R5 primary isolate YTA48P infected in CCR5-expressing human PM1 cells assessed as inhibition of virus-induced cytopathogenicity after 7 days by WST8 assay2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents.
AID1058135Volume of distribution in Jcl:Sprague-Dawley rat at 14 mg/kg, iv by HPLC analysis2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
A CD4 mimic as an HIV entry inhibitor: pharmacokinetics.
AID629100Antiviral activity against R5 tropic HIV1 YTA infected in human TZM-bl cells assessed as beta-galactosidase activity preincubated for 15 mins before infection measured after 2 days by single-round assay using luminometry2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Small molecular CD4 mimics as HIV entry inhibitors.
AID629099Cytotoxicity against mock-infected human PM1 cells expressing CCR5 by WST-8 assay2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Small molecular CD4 mimics as HIV entry inhibitors.
AID1271996Half life in rhesus macaque plasma at 75 mg, iv after 0 to 24 hrs by HPLC analysis2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
A minimally cytotoxic CD4 mimic as an HIV entry inhibitor.
AID629098Selectivity index, ratio of CC50 for mock-infected human PM1 cells expressing CCR5 to IC50 for R5 tropic HIV1 YTA infected in human TZM-bl cells2011Bioorganic & medicinal chemistry, Nov-15, Volume: 19, Issue:22
Small molecular CD4 mimics as HIV entry inhibitors.
AID1271994Volume of distribution in rhesus macaque plasma at 75 mg, iv after 0 to 24 hrs by HPLC analysis2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
A minimally cytotoxic CD4 mimic as an HIV entry inhibitor.
AID451778Inhibition of gp120 binding to CD4 in HIV1 JR-FL infected human PM1 cells assessed as binding of anti-envelope CD4-induced monoclonal antibody 4C11 to envelope expressing cell surface at 100 uM pretreated 15 mins before 4C11 addition by FACS analysis2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
CD4 mimics targeting the mechanism of HIV entry.
AID451776Antiviral activity against HIV1 KYAG primary isolate assessed as inhibition of virus-induced cytopathogenicity by MTT assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
CD4 mimics targeting the mechanism of HIV entry.
AID451774Antiviral activity against HIV1 89.6 laboratory isolate assessed as inhibition of virus-induced cytopathogenicity by MTT assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
CD4 mimics targeting the mechanism of HIV entry.
AID516485Inhibition of CD4-induced monoclonal antibody 4C11 binding to HIV1 MNA infected in human PM1 cells expressing CCR5 at 100 uM after 15 mins by FACS analysis (Rvb = 27.60)2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.
AID451775Antiviral activity against HIV1 fTOI primary isolate assessed as inhibition of virus-induced cytopathogenicity by MTT assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
CD4 mimics targeting the mechanism of HIV entry.
AID1058134Initial plasma concentration in Jcl:Sprague-Dawley rat at 14 mg/kg, iv by HPLC analysis2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
A CD4 mimic as an HIV entry inhibitor: pharmacokinetics.
AID516483Antiviral activity against HIV1 MNA infected in human PM1 cells expressing CCR5 assessed as protection against virus-induced cytopathogenicity by MTT assay2010Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19
CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.
AID1058117Half life in rhesus monkey at 13.4 mg/kg, iv by HPLC analysis2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
A CD4 mimic as an HIV entry inhibitor: pharmacokinetics.
AID1058119Initial plasma concentration in rhesus monkey at 13.4 mg/kg, iv2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
A CD4 mimic as an HIV entry inhibitor: pharmacokinetics.
AID1058118Volume of distribution in rhesus monkey at 13.4 mg/kg, iv after 24 hrs by HPLC analysis2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
A CD4 mimic as an HIV entry inhibitor: pharmacokinetics.
AID763078Cytotoxicity against CCR5-expressing human PM1 cells assessed as reduction of cell viability after 7 days by WST8 assay2013Bioorganic & medicinal chemistry, May-01, Volume: 21, Issue:9
CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents.
AID451773Antiviral activity against HIV1 3B laboratory isolate assessed as inhibition of virus-induced cytopathogenicity by MTT assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
CD4 mimics targeting the mechanism of HIV entry.
AID451777Cytotoxicity against mock-infected CCR5 expressing human PM1 cells by MTT assay2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
CD4 mimics targeting the mechanism of HIV entry.
AID1271995Initial concentration in rhesus macaque blood at 75 mg, iv after 0 to 24 hrs by HPLC analysis2016Bioorganic & medicinal chemistry letters, Jan-15, Volume: 26, Issue:2
A minimally cytotoxic CD4 mimic as an HIV entry inhibitor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (70.00)24.3611
2020's3 (30.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.63 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]